Harper Paul, Pollock Daryl, Stephens Matt
Clinical Haematology, Palmerston North Hospital, Palmerston North, New Zealand.
BMJ Open. 2018 Apr 5;8(4):e020212. doi: 10.1136/bmjopen-2017-020212.
To determine the effect of age and gender on persistence and adherence in patients taking dabigatran for atrial fibrillation.
A retrospective observational study over 4 years using refill prescription data from the National Pharmaceutical Database.
All patients in New Zealand who received dabigatran from July 2011 to September 2015.
43 339 people filled at least one prescription of dabigatran.
The proportion of patients with good adherence (treatment available at least 80% of the time), and the proportion at risk of thrombosis (a break in treatment of more than 2 days) measured 6-monthly for 3 years. Medication persistence recorded over 3 years.
Persistence was highest in older patients and showed a significant correlation with age (p<0.001); 24% over 70 years had discontinued treatment by 6 months compared with 50% under 50 years. Adherence was highest in the elderly (p<0.001) with 90% of patients over 80 years with good adherence at 12 months compared with 70% in patients aged 50-60 years and less than 60% in those under 50 years. The time at risk of thrombosis showed a similar pattern with 25% below 60 years with inadequate anticoagulation more than 20% of the time. Adherence dropped during the first 18 months of treatment with the most marked fall in those under 50 years. Adherence shows that breaks in treatment are common with 30% of men under 60 years with a break in treatment of at least 28 days during the first 12 months.
Adherence and persistence correlate with the patient's age. Those over 70 years have high adherence consistent over time whereas younger patients have significantly worse adherence which declines over the first 18 months, with the lowest rate in those under 50 years. Adherence in our study is lower than reported in clinical trials, therefore the benefit of dabigatran in stroke prevention may not be realised in clinical practice especially in younger patients.
确定年龄和性别对服用达比加群治疗心房颤动患者的持续性和依从性的影响。
一项为期4年的回顾性观察研究,使用来自国家药品数据库的再填充处方数据。
2011年7月至2015年9月期间在新西兰接受达比加群治疗的所有患者。
43339人至少开具过一次达比加群处方。
依从性良好(治疗时间至少占80%)的患者比例,以及血栓形成风险比例(治疗中断超过2天),每6个月测量一次,持续3年。记录3年期间的药物持续性。
老年患者的持续性最高,且与年龄呈显著相关性(p<0.001);70岁以上患者中有24%在6个月时停止治疗,而50岁以下患者中这一比例为50%。老年人的依从性最高(p<0.001),80岁以上患者中有90%在12个月时依从性良好,而50至60岁患者中这一比例为70%,50岁以下患者中这一比例不到60%。血栓形成风险时间呈现类似模式,60岁以下患者中有25%在超过20%的时间内抗凝不足。治疗的前18个月依从性下降,50岁以下患者下降最为明显。依从性表明治疗中断很常见,60岁以下男性中有30%在最初12个月内治疗中断至少28天。
依从性和持续性与患者年龄相关。70岁以上患者的依从性较高且随时间保持一致,而年轻患者的依从性明显较差,在最初18个月内下降,50岁以下患者的依从率最低。我们研究中的依从性低于临床试验报告的水平,因此达比加群在预防中风方面的益处可能在临床实践中无法实现,尤其是在年轻患者中。